Revvity (NYSE:RVTY) Now Covered by SVB Leerink

SVB Leerink assumed coverage on shares of Revvity (NYSE:RVTY) in a research report report published on Monday morning, Marketbeat.com reports. The brokerage issued an outperform rating and a $125.00 price objective on the stock.

RVTY has been the topic of a number of other reports. Robert W. Baird lifted their target price on Revvity from $126.00 to $127.00 and gave the stock an outperform rating in a research report on Tuesday, April 30th. Barclays dropped their price objective on Revvity from $116.00 to $115.00 and set an equal weight rating on the stock in a report on Friday, June 28th. TD Cowen increased their target price on Revvity from $123.00 to $130.00 and gave the company a buy rating in a research note on Tuesday, April 30th. Finally, Jefferies Financial Group started coverage on shares of Revvity in a research report on Monday, June 3rd. They set a hold rating and a $115.00 price target for the company. Seven equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Revvity presently has an average rating of Moderate Buy and a consensus price target of $119.14.

Revvity Stock Performance

NYSE:RVTY opened at $109.83 on Monday. Revvity has a twelve month low of $79.50 and a twelve month high of $131.96. The firm’s fifty day simple moving average is $107.32 and its 200 day simple moving average is $106.33. The company has a current ratio of 2.23, a quick ratio of 1.92 and a debt-to-equity ratio of 0.40. The firm has a market capitalization of $13.55 billion, a price-to-earnings ratio of 90.75, a PEG ratio of 2.72 and a beta of 1.05.

Revvity (NYSE:RVTY) last posted its earnings results on Monday, April 29th. The company reported $0.98 EPS for the quarter, topping analysts’ consensus estimates of $0.94 by $0.04. Revvity had a net margin of 5.49% and a return on equity of 7.37%. The business had revenue of $649.90 million for the quarter, compared to analysts’ expectations of $646.83 million. During the same period in the previous year, the company posted $1.01 earnings per share. The business’s revenue for the quarter was down 3.7% compared to the same quarter last year. As a group, equities research analysts expect that Revvity will post 4.65 earnings per share for the current fiscal year.

Revvity Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, August 9th. Investors of record on Friday, July 19th will be paid a dividend of $0.07 per share. The ex-dividend date of this dividend is Friday, July 19th. This represents a $0.28 annualized dividend and a yield of 0.25%. Revvity’s dividend payout ratio (DPR) is 23.14%.

Insider Buying and Selling at Revvity

In related news, insider Joel S. Goldberg sold 4,000 shares of the company’s stock in a transaction on Friday, June 7th. The stock was sold at an average price of $110.46, for a total transaction of $441,840.00. Following the completion of the transaction, the insider now directly owns 36,900 shares in the company, valued at approximately $4,075,974. The sale was disclosed in a document filed with the SEC, which is available through this link. 0.60% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Parkside Financial Bank & Trust acquired a new stake in Revvity in the fourth quarter worth about $25,000. Gladius Capital Management LP lifted its position in Revvity by 84.1% in the third quarter. Gladius Capital Management LP now owns 232 shares of the company’s stock worth $26,000 after purchasing an additional 106 shares during the period. CENTRAL TRUST Co bought a new position in Revvity during the 4th quarter valued at $27,000. Benjamin F. Edwards & Company Inc. acquired a new position in shares of Revvity during the 4th quarter valued at $27,000. Finally, ORG Partners LLC bought a new stake in shares of Revvity in the 4th quarter worth $32,000. Institutional investors own 86.65% of the company’s stock.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.